Q3 2024 Labcorp Holdings Inc Earnings Call
Speaker Change: and the multiple aspects of the postpartum period to personalize recovery mode, symptom tracking, and alerts, and mental health support.
Speaker Change: I am proud of our accomplishments at how we operate as an organization. We recently heard at the Fair of Supply and Freedom of Education, which recognizes organizations with an outstanding commitment to achieving a best and best-in-class ethics and compliance program.
Speaker Change: Ethics and Integrity are as a part of everything we do, and integral to our mission to improve health and improve lives.
Speaker Change: We were also proud to be named a best place to work with disability inclusion as to earning the top score of 100 by the 2024 disability equality index.
Speaker Change: In the quarter, colors the lead to implementation of Panama, removing a potential $80 million revenue headwind in 2025.
Speaker Change: Well, we are pleased with this further delay. We continue to work closely with our Creative Association to seek a permanent fix to Pamela as there is bipartisan recognition that long-term reform is needed.
Speaker Change: In conclusion, we continue to execute well on our short-term financial commitments. We're also making progress at our long term strategy.
Speaker Change: I am confident in our group opportunities and we remain on track to achieve our long term outlook. With that I'll turn your call over to Glenn.
Glenn: Thank you Adam. I'm going to start my comments with the review of our third quarter results, followed by discussion of our performance in each segment, and include with an update on our full year guidance.
Glenn: The reference we've also included additional business information that can be found in our supplemental deck on our Investor Relations website.
Glenn: Revenue for the quarter was $3.3 billion, so it increased to 7.4% compared to last year. I'm very due to organic based business growth and the impact from acquisitions.
Glenn: The Base Business Group 8% compared to the Base Business last year, driven primarily by organic growth of 4.8%.
Glenn: Operating income for the quarter was $250,000,000 or $7.7% revenue, or a 13.4% on an adjusted basis.
Glenn: During the quarter, we had 105 million dollars of restructuring charges and special items, primarily related acquisitions and launch pad initiatives.
Glenn: In addition, we had $18 million of expense for the transition service agreements related to the spin of portrayal, with the corresponding income recorded in other income.
Glenn: Excluding these items and amortization of $64 million, adjusted operating income of the quarter was $441 million or $13.4% of revenue, compared to $424 million or $13.9% last year.
Glenn: The increase in adjusted operating income was primarily due to organic demand and launch pad savings, partially offset by higher personnel costs, and the loss from a DTA. The 40 basis point that Cline and adjusted operating margin was due to a DTA.
Glenn: Excluding a BTA as well as the impact from weather and days, margins would have been up approximately 120 basis points.
Glenn: Our launch pad initiative continues to be contracted to deliver a hundred to a hundred to a hundred twenty-five million dollars a savings this year consistent with our long-term target.
Glenn: The adjusted tax rates for the quarter was 22.8% compared to 24% last year. The lower adjusted tax rate was primarily due to the geographic mix of earnings. We continue to expect the full year adjusted tax rate to be approximately 23%.
Glenn: Veterans from Continuing Operations for the Quarter were $170 million or $2 per dilute year. Adjust the DPS were $3.50 in the quarter up 4% from last year.
Glenn: Operating cash flow from continuing operations was $277 million in the quarter, which included an expected use of cash from a BTA compared to $276 million in a year ago.
Glenn: Capital expenditures total to $116 million in the quarter or 3.5% of revenue. This compares to 105 million or 3.4% in the prior year.
Glenn: For the full year, we continue to expect capital expenditures to be approximately 3.5% of revenue.
Glenn: Free cash flow from continuing operations for the quarter was $162 million. During the quarter of the company invested $458 million in acquisitions paid out $61 million in dividends and repurchase $75 million in stock.
Glenn: At quarter end we had one and a half billion dollars in cash while debt was six point eight billion dollars.
Glenn: These higher balances are due to the pre-funding of maturing death.
Glenn: During the quarter of the company raised $2 billion of long-term notes to pre-fun $2 billion of maturing debt.
Glenn: The company expects to use cash to pay down the remaining $1.4 billion of debt, maturing over the next four months.
Glenn: Our current debt leverage is 2.4 times net debt to trailing 12 months adjusted EBITDA.
Glenn: Now review our segment performance, beginning with diagnostics laboratories.
Glenn: Revenue for the quarter was $2.6 billion and increase of 8.9% compared to last year, with organic growth at 5%. And acquisitions, net of investors contributing 4%.
Glenn: The base business grew 9.8% compared to the base business last year, driven primarily by organic growth of 5.8%.
Glenn: Total volume increased 5.1% compared to last year.
Glenn: Based Business Volume grew 5.6% compared to the base business last year, as organic volume increased 2.7%. Which was negatively impacted by approximately 40 basis points from weather, while acquisitions contributed 2.9%.
Glenn: Price Mix increased 3.8% versus last year due to organic based business growth and acquisitions that was partially offset by lower code testing.
Glenn: These business organic price mix was up 3% compared to the base business last year due to mix. As we benefited from lab management agreements and increased in test per session, and SOTAR testing growing faster than we did.
Glenn: Diagnostics suggested operating in April for the quarter was $387 million or 15.2% of revenue compared to $386.6.5% last year.
Glenn: I just had operating margin was down 130 basis points due to in detail and the unfavorable impacts of days and weather.
Glenn: Including these items, margins would have been up around 80 basis points as the benefit of organic demand and most bad savings was partially offset by higher personnel costs.
Glenn: Now, I'll review the segment performance of Biopharmal Laboratory Services.
Glenn: Revenue for the quarter was $738 million and increase of 2.6% compared to last year due to an increase in organic revenue of 2%. And for our currency translation of 0.6%.
Glenn: The revenue growth was driven by continued strength in Central Lamps, which was up 9%, while early development was down 11%, primarily due to higher than normal cancellations in prior periods.
Glenn: I'll ever early development revenue increased the consciously from the second quarter and we continue to expect it to grow year over year, beginning in the fourth quarter.
Glenn: By a farm adjusted operating income for the quarter was $121 million or $16.4% of revenue compared to $190.5.2% last year.
Glenn: I just had operating income and margin increased due to organic demand and launch pad savings, partially offset by higher personnel costs.
Glenn: We ended the quarter with a backlog of $8.1 billion and we expect approximately 2.6 billion of this backlog to convert in a revenue over the next 12 months.
Glenn: The Trailing 12 month book to build was 1.02
Glenn: and the
Glenn: Now, we'll discuss our updated 2024 Foyer guidance, which assumes foreign exchange rates affected as of September 30, 2024 for the remainder of the year.
Glenn: The Enterprise Guide is also imposed the impact from currently anticipated capital allocation, including acquisitions, share purchases and dividends.
Glenn: We expect Enterprise revenue to grow 6.6 to 7.3% compared to 2023. Versus prior guidance, the midpoint is unchanged as a benefit of 20 basis points for a foreign currency is being offset by a negative 20 basis points from weather.
Glenn: We continue to perform well and diagnostics with revenue expected to be at 7.2 to 7.8% compared to 2023.
Glenn: This is an increase at the midpoint from our prior guidance of 10 basis points due to the improved outlook within diagnostics.
Glenn: The acquisition of select assets that by reference, that was previously only included in the enterprise guidance until the transaction closed, is benefiting diagnostic growth by 30 basis points.
Glenn: This is being offset by the unfavorable impact from leather of 30 basis points.
Glenn: We expect by a farmer revenue to grow 4.7 to 5.6% compared to 2023.
Glenn: The midpoint of our guidance increased 80 basis points due to the favorable impact from foreign currency of 100 basis points, partially offset by a slow recovery in early development of 20 basis points.
Glenn: We continue to expect early development to grow revenue year over year beginning in the fourth quarter.
Glenn: We expect enterprise margins to be slightly down year over year with diagnostics margins constrained by a VTA and weather. We expect by a farm of margins to be up year over year.
Glenn: Our guidance range for adjusted EPS is $14.30 to $14.70.
Glenn: We have decreased the midpoint of guidance by 10 cents due to the estimated impact from weather of 15 cents.
Glenn: Our free cash flow guidance range is 850 million to 980 million dollars.
Glenn: In summary, we expect to drive continued profitable growth in strong free cash flow generation that will be used for acquisitions that support our strategy and supplement our organic growth while also returning capital to shareholders through our shared-references program and dividends.
Glenn: Operator, we will now take questions.
Speaker Change: Thank you. As a reminder to ask the question, please press star 1 1 on your telephone and wait for your name to be announced. To withdraw your question, please press star 1 1 again. Please stand by while we can pile the Q&A roster.
Speaker Change: the
Speaker Change: and our first question comes from Anne Heinz, that Missouho, your line is open.
Anne Heinz: Good morning Adam
Adam: Good morning.
Anne Heinz: Just heading into 2025, is there any specific head of winds and tailwinds that you would like to call out?
Speaker Change: and then secondly, I'm sure you're seeing some of the late stage probably traded peers have not done really well this quarter
Anne Heinz: and Reverend E. Groath is declining or I should say accelerating.
Anne Heinz: but it seems like the opposite is happening to your central lab. How should we think about the impact of what's happening with some of your customers? From a time of perspective, do you expect that to impact revenue? Is there a lake? Six months, 12 months, how should we view it in the future? Thanks.
Speaker Change: Sure, I'll start with 2025 and so first of all I feel great about the momentum that we have in both our diagnostics and central laboratory business.
Speaker Change: and we expect early developments from going to Fort Porter and will grow as we go to 2025. We're not giving any 25 guidance today.
Speaker Change: But as you're looking at a longer term guidance where we have organic revenue growth of 3.5 to 5.5% plus another 1.5 to 2.5% growth for the internet and growth, we remain on track. And we're going to be entering 25 with 3-0 momentum and strength.
Speaker Change: I think about the Central Laboratory business, it continues to perform very well. Central Laboratory have very strong growth year over year of 9%.
Speaker Change: I would say that that's based off of a easy compare last year because as you recall last year there was a lot of sites that didn't have the ability to roll patients, they had staffing issues and so forth.
Speaker Change: But as we look forward into the future and I look at the long term guidance for BLS, I expect Central Labs will be consistent with that guidance and so can King of Broke. If you look at the Central Lab books, we have solid orders, we have good consistent win-rikes.
Speaker Change: and we are a leader in that field and in that field the majority of our business is with large de forma. It's much less with the smaller biotechnology companies.
Speaker Change: Great, thank you.
Speaker Change: Thank you.
Speaker Change: Our next question comes from the Seguil of J.P. Morgan, your line is open.
Speaker Change: Warning, we're sorry.
Speaker Change: Just wanted to follow up on in VK and the margin for Gretchen. You talked about the impact in the quarter. As I think about going into 25, like, how should I think about one that margin progression? And then secondly, is there anything to call out when you think about the mix in the diagnostic business?
Speaker Change: and we look at the price for a wreck coming in much better than what he had into the pages in our model.
Speaker Change: Yes, so let me start first with the V-Tase. So, you know, we continue to be really excited about their science, the genetic testing solutions and technology that they have, and it really aligns with us strategically. The integration is going...
Speaker Change: extremely well, we're on track with all the integration metrics that we have in place. If you look at the financial metrics, we're performing as we expected, based on what we provided guidance last quarter. And as you look at this year, we expected to be in fact about 40 basis points.
Speaker Change: Negative, but as we go to next year, we expect in BTA to be slightly afraid of.
Speaker Change: So you can assume that it's negative in the first two quarters of the launch and it's slightly agreed up for the full year that it'll take us a little bit of time as it goes through the year before you see that equation occur.
Speaker Change: But overall, we remain very bullish about that acquisition and the revenue growth will be about 10% as we think about next year as well.
Speaker Change: and then in terms of our mixed-elastment, provides you comments.
Speaker Change: Yes.
Speaker Change: First, I'll also just wrapping up on the MbTas, as Adam commented that, yeah, we would expect margin improvement sequentially going forward. So each quarter that we have it, we integrate the business, it'll improve.
Speaker Change: will still show negative comps on margin year on year through the first half of next year just until it annualizes. And then at least at once it annualizes you'd expect to see that margin improvement or be a tal one to margins.
Speaker Change: and the second half of the next year.
Speaker Change: with the price mix. We actually had a good top line growth within diagnostics overall. If you look at our base business organically.
Speaker Change: We grew around 6% and that was pretty evenly split between utilization. Volume was up around 2.7% and even that was constrained by weather around 40 basis points. But to your alert comment, the Nixon pact we were up around 3%.
Speaker Change: and really what drove that this quarter more than anything was the inhospital lab management agreements which we continue to do and we treat that as price mix.
Speaker Change: but we've also seen the steady increase in our test per session, which we've seen over time, that continues to progress and we continue to see growth in more of our SOTR or ex-business growth faster than our routine. So really the combination of those three things is what's what drove the favorable mix of this quarter.
Speaker Change: Thank you.
Speaker Change: Thank you.
Speaker Change: Our next question comes from Michael Choney of Leering Parkner's July is open.
Speaker Change: Morning Michael!
Michael Choney: Thank you so much for taking the question. Maybe it's just to come at the margin question a different way. I know it's hard because...
Speaker Change: and moving pieces, especially stuff that would save that out of your control, out of the D.T.A. But as you think about the savings that you've been able to generate on the cost side, that you think about.
Speaker Change: where you've landed, you know, I think it hurt 120 basis points of...
Speaker Change: Underlie, margin expansion in your view, x and b-tax, whether etc.
Speaker Change: Where do you think have been the most successful sources?
Speaker Change: of margin expansion. How do we think about the pull through on what still remains an elevated revenue growth?
Speaker Change: Level on incremental pull-through versus...
Speaker Change: Restructuring and I guess...
Speaker Change: is a little bit. How do we think about the cost cutting impacts of how to be on the D-sake playing forward into 25, both with launch pad and outside.
Speaker Change: Yeah, so in my God, I'll take a...
Speaker Change: First kind of an enemy when I had as well, but we actually do feel very good about the underlying performance of the company. And to your point, we have a bunch of headwins that we've identified that we could obviously be more non-operational. The strategic acquisition that we did with the VTA, the impact of weather.
Speaker Change: This quarter in actually will also have a quarter impact in the fourth quarter from just days. So kind of timing related. And so that gets to that 120 basis point expansion that you commented about. But the underlying business when we take those out and also obviously still have a little bit of a headwind from Coded testing.
Speaker Change: that's now leveled off but still year over year. It's a negative impact.
Speaker Change: But the underlying business we're benefiting from the top-line growth we're benefiting from our launch pad initiatives, we're still on track to 125 million of our launch pad savings.
Speaker Change: So as we think about operating leverage, ideally we target kind of around a gross margin. When you kind of peel off those unusual items, if you will, or the headwinds that we had, we're operating in the high 20s. And track the old stronger even in the third quarter, but we're kind of in the ballpark of our gross margins. So we think underlying our business.
Speaker Change: and we're where we need to be. What's interesting as well is a lot of the headwinds that we're having this year in 2024.
Speaker Change: will become tailwinds to our margins next year. So we still expect our underlying performance to be good. But then when you think about in VTay, when you think about days, obviously if we would have normal weather, all those three headwinds that we had this year will become tailwinds from our Gens next year.
Speaker Change: I'm not going to think I would add to that to this. When we talk about lawns pad
Speaker Change: It really is continuous.
Speaker Change: and we know as we go into the future we're going to have to continually find ways to reduce cost and through margins.
Speaker Change: and I think with all the work that we're doing with technology, with some of the work that we're doing with artificial intelligence, we see other opportunities now above and beyond what we've talked about in the past to continue to find ways to do this possible and report. So that's just something that's built into our DNA as a company and we're going to continue to find ways to reduce costs where we can.
Speaker Change: Great, thank you.
Speaker Change: Thank you.
Speaker Change: Our next question comes from Patrick Donnelly of City, your line is open.
Patrick Donnelly: Hey guys, good morning. Thanks for taking the questions. I want to just ask them on the diagnostic experience.
Patrick Donnelly: just for core utilization trends you guys are seeing onto the weather impact moves things around a little bit. But what you're seeing there and just the expectation going forward, you know, certainly looking.
Patrick Donnelly: You know, either turning towards 25 as you talk a little bit about here, any reason why you can be inside that LRP as you think about the utilization rate and heading into next year.
Speaker Change: Yes, you know, Patrick, as you look at utilization rates, you certainly see acceleration in healthcare overall. And the question is, what hospitals have seen and other parts of healthcare will that continue? I would expect at some point that will slow down a bit the more historic levels.
Speaker Change: But at the same time with our business I believe we're seeing share increases in particular as we do more of these hospital deals and the local regional laboratory deals.
Speaker Change: So, when you look at a longer term guidance for diagnostics, we expect organic revenue growth of 2.5 to 4.5%.
Speaker Change: and then a top of that inner panic, which we've actually increased our long term inner panic, growth expectations, is certainly it was one to two percent now that we have at one and a half to two and a half percent. So you look at those numbers that we tell you that we expect continued strong momentum as we move forward with the business.
Speaker Change: Great, thank you, Glenn.
Speaker Change: Thank you.
Speaker Change: Our next question comes from Aaron Wright of Morgan Stanley, your line is open.
Speaker Change: Good morning. Good morning. He spoke to some of the pricing dynamics in ASP's but
Aaron Wright: I guess how would you characterize just underlying kind of current pair of relationships in the pricing environment around those? And I think you have a new blues relationship. I guess anything else to call out or what is that ad for you or anything else to call out from a pair of relationships standpoint? Thanks.
Speaker Change: Yes, sure. Now, we continue to feel very good about our managed care discussions and the contrast that we're going to go shaded. We're very confident that the renewals that we've secured are good terms. And if you look across everything we've done this year, we believe as we report net net, we're neutral society positive, which historically that has not been the case. So, I feel great about the different managed care discussions that we've had this year. Our position as we go into 2025 is strong. I don't see any major contracts that I'm concerned about. So, I think that the momentum will continue.
Speaker Change: Great and then on early development I guess can you part out a little bit more how you're thinking about the quarterly progression from here just
Speaker Change: and giving some of the lumpiness across Canada that business. They get how you think about the longer term performance across early development, has anything changed in terms of your long term goals and then how you get to kind of that fourth quarter ramp.
Speaker Change: I'll get some comments on an L.A. for Glenn to jump in as well. If you look at our Holy Drill Business, we certainly saw sequential.
Speaker Change: Positive
Speaker Change: wrote in terms of revenue.
Speaker Change: We saw a lesson of a decline in third quarter as a percent that we saw in second quarter.
Speaker Change: As we move into fourth quarter, we have good insights to the studies of underway, so like we have to get new studies to understand what fourth quarters we look like. Based upon what we see.
Speaker Change: Today we expect that there will be growth in early development in the fourth quarter. Now to be fair, it's often a relatively easy comparison versus fourth quarter of last year.
Speaker Change: and as we go into next year and the book to build continues to build and the cancellations continue to hold them and we would expect to see growth as well but also based upon an easier compare because this year it continued to struggle for several quarters.
Speaker Change: So over time we continue to have good expectations for that business. We are a leader in that field. I believe that the biotechnology companies will just raise your continued to do well. And over time that business has had some cyclical ups and downs, but over time it's a very good business.
Speaker Change: Yes, the only thing I'd add is you think about even just the segment, the implied guide for the fourth quarter is revenue growth of, called at 9.5% so obviously a lot stronger around 6.5% higher than what we had for the first nine months.
Speaker Change: Current Cs around 2.5 points of that, but the underlying 4% that really the strong improvement is being driven off of early development.
Speaker Change: You would have seen that on the 9 months we're down around 11% in early development. Business public expect positive year over your growth in the fourth quarter. In his Adam said we have a soft comp in the fourth quarter. But more importantly, we saw sequential growth in ED in the third quarter from the second. We expect to see sequential growth again in the fourth quarter.
Speaker Change: Obviously given the time of year with the fourth quarter we're effectively now executing on our backlog.
Speaker Change: where this has been a business a little bit more difficult to forecast because of the short nature of the studies.
Speaker Change: So you count on the new business coming into turn into revenues in the same quarter. So we feel pretty good about the outlook, the growth.
Speaker Change: and has added a long term for bioforma, we're looking at the midpoint of our growth rate of 6%. So we're already there in doing well within Central Out ED. Obviously, it's now going to be positive and you would expect it in the lower comps there to be even a little bit higher growth rates over the next couple of years.
Speaker Change: Coming from ED, including from the margins, again, one of the benefits of the tailwinds, as we think about 25, just what that top line growth will also get positive margin improvement there as well.
Speaker Change: Okay, great, thank you. Thank you.
Speaker Change: Our next question comes from David Westenberg of Piper Sandler, your line is open.
Speaker Change: Morning Davis.
David Westenberg: Good morning and thank you for taking the question. Just another one on the LRP and as we look into next year, it sounds like you have a lot of favorable things in the environment. You raise your inorganic look because of lab acquisition. Pamela looks like it's on hold for next year. Bio-tec funding is least not getting worse.
David Westenberg: Is there anything else to flag in the industry or lab course specific?
David Westenberg: that would might be of surprise into the LRP and then can you just remind us the factors?
David Westenberg: Associated with the high end and the low end of the LRP because it definitely seems like all the macro factors are working kind of in the favor. Thank you.
Speaker Change: Yes, so give a document specific 2025 guidance today which we'll give in February next year. We have momentum and you can feel the momentum, you've seen it over the past few quarters, diagnostic business continues to perform well both organically and energetically, central laboratories, performing well, and EDU will be back to growth.
Speaker Change: and I think about Pamela, we still have an impact of Pamela in a long term guidance. And we just pushed it out of the year, there's another year.
Speaker Change: So if Pam worked to be pushed out again, obviously that would have a positive impact on our longer term guidance.
Speaker Change: but until such a point that I'm confident that there won't be an impact of payment in 2026, we continue to keep it in our longer-term guidance and model. We continue to watch the broader trends, the utilization rates, the business development that we're doing, and the trends remain strong.
Speaker Change: Farming surprises we remain confident as we look at the aluminum we have.
Speaker Change: Yeah, no, I would agree. The other thing is you look at normally the upside ranges in the downside obviously is demand driven to get to the upside or maybe someone for seeing headwinds and
Speaker Change: As Adam said, where we sit today and as again we'll comment more about 25 which would be the second year into our long term.
Speaker Change: Um...
Speaker Change: Rangers, if you will, we feel very good about the Rangers.
Speaker Change: Just even from a general profile of that mid-Singles-Jetop line group.
Speaker Change: Organically, March and Improvement Capital Allocation that will help fuel topline growth through acquisitions as well as from cash.
Speaker Change: for Free Cash Flow to get to a double-digit earnings for Sherr County Growth Profile.
Speaker Change: So we feel very good and even with some of the headwinds, tailwinds is Adam Schechter, we get the benefit.
Speaker Change: from Panadine Delay, but still within the range from a margin profile and revenue. And the flip side is on a detail, Mr. Teachick deleted, but that would be collet dilute up to the margins if you will, relative to our general profile that we would put in there.
Speaker Change: So, overall, you know, net net, we feel pretty good about the ranges that we have.
Speaker Change: Thank you so much.
Speaker Change: Thank you.
Speaker Change: are next question comes from Jack Mehan of Nefron Research, your lines open.
Speaker Change: Morning Jack.
Jack Mehan: Good morning.
Jack Mehan: When to start with in V-Ti for Glenn within the M&A, contribution in the quarter can just call out how much of the sales came from V-Ti. I penciled in 45 million as that of G'd-Bogi.
Speaker Change: and then for Adam the Ferrettaary Market is pretty competitive, just any perspectives and the early days of the deal. How any share of ships are going? Thank you.
Speaker Change: Yeah, I'll take the check the first one on a D.T. and Adam, I think mentioned it in his opening comments
Speaker Change: We're pretty much in line with expectations so we originally said that for the year we'd pick up around 120-ish of
Speaker Change: Revenues and it would be weighted kind of 50 and 70 between the 3rd and the 4th, so your number for the 3rd is in line with what our expectation is. But across the board for in detail we feel very good about the integration that's going on. What was expected and continued to drive to get that to be obviously positive from a earnings in a margin standpoint next year?
Speaker Change: and Jeffords regards to the American market and we'd be competing in that market for quite some time.
Speaker Change: in B.K. was an additional way for us to be larger, a competitor in that market. So we know, well, we know how to compete in it, we know how to win in it. It's still early days, frankly, when you look at revenue, but so far so good. And our customers seem to be pleased and now how, you know, laptop testing capabilities available to them, we're continuing to work in the customer experience. So it could become much easier for the customers over time to order directly all the tests that they might want for a patient for warmly self or for oncology. So I think over time.
Speaker Change: We're going to continue to do very well. The 10% growth that we expect in revenue is almost what the market is growing. So my hope is over time will be able to accelerate that, but in the meantime we're facing the same growth about the market rate.
Speaker Change: [inaudible]
Speaker Change: What the moving perks would suggest number may be for 2025. Thank you. Yes, Joe Jack. I think on our last call when we knew we were going through the financing at that time, we kind of talked just in line of around 210 of interest expense for this year growing to 240.
Speaker Change: We did all of our financing so we actually feel good about where we came out. We raised the $2 billion.
Speaker Change: We actually had a book of over $8.5 billion so we were able to get tighter pricing and we had the market a good time. So, directly assume that we're coming in a little bit better on the interest expense this year and therefore, next obviously the bulk of it will be annualized for next year, but the year over your change should be comparable.
Speaker Change: the absolute number should be a little bit favorable to what we shared before.
Speaker Change: God it. Thank you.
Speaker Change: Thank you.
Speaker Change: Our next question comes from Pito Chickering of Deutsche Bank, your line is open.
Speaker Change: Morning Peter!
Pito Chickering: Hey, good morning guys, it's take my question.
Speaker Change: If I got to manage care or question, play different than Aaron's. It compared to what we were talking about, expanding.
Speaker Change: and the Dick Deal with a large national pair in three states where it looks like you had an exclusive deal. I'm losing a state where it looks like you won.
Speaker Change: So looking at the total volumes that managed care for 2025, well they be headwinds or tailwinds with a contract movement that occurred that's occurring for next year.
Speaker Change: Yeah, so Peter, I just looked across all of our...
Speaker Change: a contract that we negotiated as we went through this year. Net, net, I think it was really good. And in fact it's going to be neutral, you know, slightly positive for us. If you look at areas, you know, in general,
Speaker Change: I prefer non-explusive contracts overall and I've been saying that for five years now because I think when you have exclusive contracts at mass organizations it just leads to price erosion every three or four years.
Speaker Change: Where if you have open contracts, I think you can compete in the marketplace and we can compete very well in the marketplace.
Speaker Change: and when exclusive contracts open up, typically the rate structures change as well, so there's not significant downside in many ways in that case also. So I feel very good about our managed care position. I feel very good about the momentum that we have in managed care as we go into the next year.
Speaker Change: Good great, thanks so much.
Speaker Change: Thank you.
Speaker Change: And our next question comes from Andrew Bratman of William Blair, as long as open.
Andrew Bratman: Hi guys, we're warning, thanks for taking the questions ahead. Adam, maybe just following up on your comments related to the oncology offering.
Andrew Bratman: You guys have expanded that portfolio nicely over the last few years. So, maybe just sort of talk about the trends you saw this quarter and those advanced cancer tests and how are you sort of thinking about future growth there over the coming quarters and years. Thanks.
Speaker Change: Thank you, Andrew. If you look at oncology, we really do have a very broad menu of oncology offerings. What it'd be, the basic testing and routine testing that you need for oncologists or the more esoteric testing, whether it be lipid biopsy, solid tumors, we continue to have a very strong broad portfolio.
Speaker Change: When I think about oncology, I don't look at any one test as the answer to how we're doing. I look across all of the oncology business that we have.
Speaker Change: and if you look at Crossover Business, we're seeing that business growth faster than our underlying routine testing business. In general, what the Sceptor testing is growing faster. I think what you want to make sure is that when you offer a very high Sceptor of Faculty Test,
Speaker Change: of position has your body done. Off to order all the other tests at the May 1.
Speaker Change: and we'll put yourself in a position, shoes, and you'll say...
Speaker Change: Do I want to do a multiple different ordering systems to order all the different types of I might need for an ecology patient.
Speaker Change: Well, do I want to have one system and get one report with all the results on it versus getting multiple reports across different systems? I think the advantage that we have over time is the full portfolio of ecology offerings.
Speaker Change: So, what I look at is not only individual office that we have, but how do we do across the entire portfolio, including including the team tests that you would do for quality patients, like white blood cell counts and so forth. So overall, it's a very good franchise for us. I expect it to grow faster than the overall underlying rate of diagnostics, and it will continue to be an area of focus.
Speaker Change: Good, thank you.
Speaker Change: Our next question comes from Kevin Kalliando of UBS, July 9th.
Kevin Kalliando: Good morning guys, thanks for getting me and I appreciate it. I just wanted to clear up a couple of things that I have questions on. The 80 basis points margin that you called off her diagnostics.
Kevin Kalliando: X weather and in V-tay that's a fantastic number. Wasn't there also a negative impact from calendar and sort of payroll days in the like as well? Like with the margin it actually been better like like for like.
Kevin Kalliando: Now Kevin, when we gave the 80 basis point improvement, excluding we didn't include the days. So in VTag, whether in days combined for call it 210 basis point headwind.
Kevin Kalliando: So we would have been up 80, but that still absorbs our being called a 30 basis point impact from COVID as well. But that's why when we talk about the underlying improvement in our margins, we feel good about how the businesses perform and we just have these headwins that again next year will hopefully turn it to Owens.
Speaker Change: Well, that was sort of my first follow-up was fourth quarter we.
Speaker Change: should have a little bit of this. And then next year, can you sort of quantify what the calendar at least in the payroll might be? Like in terms of a positive, is it a couple days? How should we think about that?
Speaker Change: So we had, you know, the big impact this year was we had two days of unfavorable payroll. Next year we'll have one day of favorable payroll. So it'll be a positive year over year.
Speaker Change: in 2025.
Speaker Change: Great, okay, that's super helpful. And I just one thing on in VTA I wanted to clarify. I understand that there's a creation
Speaker Change: Is that an absolute dollar's meaning next year, if in detail it was just a stand-alone, it would actually be AOI positive or is the increase in just on a year over year basis versus the delusion that you're seeing in the third and fourth quarters.
Speaker Change: I mean, like I'm not, I'm positive.
Speaker Change: Yes, now Kevin, when we say that in VTay will be a creative in 2020 by that's on a stand-alone business, fully funded, fully burdened with the cost for the acquisition.
Speaker Change: So slightly creative last year where it's got our next year, we're a stiluit of this year. When we talk about margin, similarly, we expect to have obviously positive margins generating positive earnings.
Speaker Change: So in the first half of the year, margins will still be, even though that's either positive, they'll still be a headwind to overall margins. They're not back up to diagnostics margins, but first half.
Speaker Change: But then once we get into the second half of the year, they'll start to be positive for diagnostic year over year because we'll be coming to negative margins. We're now there, they're positive margins. But a credit earnings in absolute terms.
Speaker Change: Perfect, that's great. And one last quick one, launch pad versus inflationary pressure. I know there was a period of time when launch pad wasn't necessarily able to keep up.
Speaker Change: was able to keep up in three-cue to anticipate launch pad hitting its target being a at least being able to offset the wage and inflationary pressures.
Speaker Change: We've actually been tracking pretty good, you know, that's 1225 of year
Speaker Change: of Launch Pad Savings is comparable to kind of a three little bit over 3% call it merit increase. This year again, person I'll cost for hiring part because of the days, but when you take out days you just focus on the merit. Launch Pad does track and help offset those costs.
Speaker Change: Guys, thanks so much, super helpful.
Speaker Change: Thank you.
Speaker Change: Our next question comes from Elizabeth Anderson of Evercore ISI, your line is open.
Elizabeth Anderson: Hi, good morning, thanks for the question. I have a question about your consumer business. Obviously, that's a continuous decision of nice momentum. Can you talk about sort of your expectations for that as we sort of round out this part of a year and sort of where we should think about that from sort of a margin contribution and perspective?
Speaker Change: Yes, so if you look at our consumer business, I'll focus on the left for fun to me.
Speaker Change: we continued to add testing options on the on-demand system so we announced two new ones in the quarter, the organizing hormones as well as a separate and we launched a couple test last quarter and we continued to look for new tests to bring into that platform.
Speaker Change: We don't break out the revenue on demand because it's still not of a material amount that makes sense for stuff. Break out, but the growth rate of that business is pretty substantial. And if it does reach a point or when it does reach a point where we think it's worth while to model and to provide for your models, we'll break it out at that time. But we're going to continue to add tasks to continue to grow while it's just not a critical match yet.
Speaker Change: Okay, and then just from a margin perspective is that it's sort of like how do we think about those margins like these are either corporate average and as you said it's still small but
Speaker Change: and again it's kind of like that Elizabeth given the size of it relative to the big business we have. It doesn't round really on the margin. Obviously we're making investments in that part of the business that will help fuel the growth but you won't really see the impact on the margin.
Elizabeth Anderson: got it perfect thank you very much
Speaker Change: Thank you.
Speaker Change: A next question comes from Eric Kaldwell of Bear, your line is open. Morning Eric.
Speaker Change: Eric?
Speaker Change: Eric, your line is open. If you're muted, please unmute. Can you hear me now? Can you hear me now?
Eric Kaldwell: Hey, good morning guys, sorry about that. So if you'll allow me to squeeze in two quick ones first, just street to little bit focused on your relationship with law greens.
Eric Kaldwell: Don't think you've mentioned that on this call but obviously Walgreens is closing a number of stores over the next few years and I think you have about 400.
Eric Kaldwell: and the United States. So just any comments on that and that and that relationship is. Second, on the employer testing related business.
Speaker Change: I've been reluctant to really highlight some of these kind of nitpicky things that are smaller.
Speaker Change: That's obviously been a headwind and I think masking some of even better growth, but when will those comps possibly normalize? When do you think you get to more of a basal raid in the employer testing facing businesses?
Speaker Change: You know, might that also be a favorable conc for 2025.
Speaker Change: Okay, so let me start with the Walgreens Special first. I would continue to have a good relationship with Walgreens. You know, we start a relationship back in 2017 and it continues to be a very good discussion between our teams.
Speaker Change: Obviously they're making some strategic decisions. The goodness for us is that we've increased our capabilities at our standalone service centers.
Speaker Change: So if you look at the technology we've added, the ability for people to check in, the ability for people to check in remotely, and we've done a lot of the MPS scores of our standalone PSEs have actually increased over time and it continued to increase.
Speaker Change: So, at this point we do have about 400 PSC service centers in Walgreens. We expect it to be minis, but not all those who continue as they make their decisions. If we have to stand up from standing low PSC, it's not a problem for us to do it. We know how to deal with it all the time.
Speaker Change: with regards to employer casting for us, it's still relatively small part of our business. We do continue to see Australian at business and the counts are...
Speaker Change: Fields, difficult but it's so small that it's not worth rush to break it out. In terms of overlapping, it's hard to say, I can talk to say what the bottom could be on that to be honest. But I don't think it all adds much positive or negative as we think about 20.25.
Speaker Change: Yeah, I agree that it's definitely when you think about this strength of our organic demand and volume this year, that's what the head went up in Blur's services. So again, it speaks to it's not a big headwind, but similarly as we go next year, even though we would hope an expect to see improvement there, you're not going to see a big.
Speaker Change: to Alan from that as well.
Speaker Change: I'm not really worried about the Walgreen situation but if I could just ask, would it not make sense that perhaps you're in some of their better and higher traffic stores I eat those less likely to be facing closures?
Speaker Change: So, when we work with them to decide the source that we choose, we choose stores that are mutually beneficial to them and to us. So, areas where they see a lot of volume, source where they know that if they have a service center there, they'll get even more volume and a high volume source. So, when we first choose those, we chose the 400, we're very deliberate. We work very closely with them to strategic and choose those stores. That's why I'm pretty good about where we are with them.
Speaker Change: and also from that, you know, to the extent it would be a store would be impacted where we would have a patient service center. We'll have the opportunity to find another store with them to go into that we're not that could be in close proximity or we'll also have the option of just setting up the patient service center in that location that would be outside of where they are. But to your point it's we're not expecting many to be impacted but frankly we just don't know yet and once we do.
Speaker Change: and we'll roll it out from it.
Speaker Change: Thank you.
Speaker Change: Our next question comes from Stephanie Davis of Barclays, your line is open.
Speaker Change: Morning Stephanie.
Speaker Change: and Brandon, thank you for your question guys.
Stephanie Davis: I was hoping we could dig into BLS again. There's been some noise in the background pricing from some of your peers. So I was hoping to give them the upside you'd come and what you're seeing in pricing may be white, differentiate. And any further color you can give around from the metrics around orders and calculations. Thanks.
Stephanie Davis: and the other one.
Speaker Change #101: Let me start with the second question first. So, give up at our training 12 months, but to be able is a 1.02.
Speaker Change #102: That's with the quarter being at a 496. So we had a relatively easy compare versus the same quarter last year.
Speaker Change #103: The book to Bell remains healthy for both businesses.
Speaker Change #103: We have good consistent win-wings, we have solid orders across the businesses. So if you're good at it, I'd love to go into the future for those businesses.
Speaker Change #103: The thing I would say is that quarterly book to bell changes. So it was an easy compare to this quarter versus last quarter. In fourth quarter we expect to have sequential growth versus this quarter in dollars and also in terms of the book to go for the quarter. But it could be a very rough.
Speaker Change #103: Comparator versus Fort Quarter of last year. That I feel like a first quarter of this year versus 2025, it'll be a much easier comparison. So, what I would say is, overall, the book to Bill remains healthy, but you do see plus, so, you can see, quarter over quarter, and that's going to continue for the next couple of quarters and moving forward.
Speaker Change #103: with regards to pricing, you know, I'll start with our early development business. In general, what capacity is not fully utilized, you see some pricing pressure, we see some pricing pressure but at the same time because the price of any speeds have come down pretty significantly.
Speaker Change #103: and the NPP is not in touch us because it was just a capture for us.
Speaker Change #104: are customers of seeing a price decrease.
Speaker Change #104: just face upon the cost of any disease, which I think helps us with some of the pressure that they're feeling.
Speaker Change #104: and it's central laboratories, you know, we continue to have some long-term contracts over time. We have lots of long-term agreements, so there's always going to be pricing pressure there. We're going to always look for ways to reduce costs as we face those pressures. But overall net net, the momentum in central assets is very strong and we expect the early development business to be back to growth next quarter.
Speaker Change #104: and Glenn.
Speaker Change #105: Thank you.
Speaker Change #106: And our next question comes from Michael Riskin of Bank of America, your longest open.
Michael Riskin: Good morning, good morning.
Speaker Change #108: Hey, morning, this is John Kim from Ford Michael.
John Kim: So in the day seems to be progressing well. So looking ahead, you've talked about the M&A contribution to still be 1.5 to 2.5% here. Where will your priorities lie? Perhaps like any geographic exposure that you would want to increase.
Speaker Change #110: Hi, now what I would say is, you know, we continue to have a very deep business developed with pipeline.
Speaker Change #110: The Vast Vast majority of it is in the hospital and health systems, local and regional laboratories.
Speaker Change #110: and that's where our focus is when it comes to deals, we're looking for things that are predestined in the first year, return or cost a capital in two or three years that we know how to integrate really well. What I'd say is something like in B-Tain is not typical, we don't typically do a deal that would be the reason of the first year, those are not the types of deals that we would typically be interested in if it's strategically aligned and a one-off of consideration, but in general, what we're really looking for is a little hospital, regional, local laboratories.
Speaker Change #111: and then also great to hear that the launch rate launch rate savings are on track to offset the wage inflation. But wanted to ask how the front line work over to an overrate has been like.
Speaker Change #112: The launch pad is being very effective in helping offset the wage rate.
Speaker Change #113: We have seen improved call-ed attrition, especially within our biopharmicide, kind of actinormal levels of pre-pandemic.
Speaker Change #114: We've seen nice progress within the diagnostic side of our business.
Speaker Change #115: At the end of the year, the two are pointed to the right direction, especially the front line workers. It is more competitive. They have a lot of other choices to...
Speaker Change #115: to try and find higher hourly wages at different industries, even not necessarily just what we do here. So we continue to work hard on making it a good, inclusive experience we were focused on our teams.
Speaker Change #115: Obviously, the longer we keep people working for us, the more loyalty and the more likely they stay. So overall, it's being managed. It is part of the overall increase in the labor environment cost, but we continue to make progress on it.
Speaker Change #116: I'd appreciate that.
Speaker Change #117: Thank you.
Speaker Change #118: The New York Times
Speaker Change #119: Our next question comes from a Brian Tankleot of Jeffries, your line is open.
Speaker Change #120: Morning Brian
Speaker Change #121: Hey guys, this is Megan on for Brian Thanks for taking the question at the end. Can you guys just speak to your M&A pipeline? You guys obviously had a lot of deals over the last year. We'd like to just know how many of you have any visibility of what that's going to look like into 2025.
Speaker Change #122: You're home again, so we continue to be
Speaker Change #123: very optimistic about our pipeline of deals, particularly in a hospital.
Speaker Change #123: Local Regional Laboratory businesses. And if you look at what we said is going to happen in a long term outlock, we've actually increased the revenue growth that's going to come.
Speaker Change #123: from the acquisition site that we have.
Speaker Change #123: So we expect historically.
Speaker Change #123: The Interagant Approach, we want to 2% we've actually raised that in a long term guidance, which now will be 1.5 to 2.5%. This survey was 1 to 2% now, it's 1.5 to 2.5%. I think that just shows our confidence in the pipeline of the else that we have. It's impossible to predict the exact timing, but I look forward to talking about those in the future.
Speaker Change #123: Thank you.
Speaker Change #124: Thank you. This concludes the question and answer session. At this time, I'd like to turn it back to Adam Schechter for closing remarks.
Adam Schechter: I thank everybody for joining us today and I hope you see we continue to advance our mission to improve health and improve lives and we look forward to updating on our fourth quarter of full year 2020 for financial results as we get into the new year. I look forward to seeing you all soon. Thank you.
Speaker Change #126: This concludes today's conference call. Thank you for participating and you may now disconnect.
Speaker Change #127: The New York Times The New York Times
Speaker Change #127: The
Speaker Change #127: The New York Times